View ValuationNippon Shokubai 将来の成長Future 基準チェック /16Nippon Shokubai利益と収益がそれぞれ年間4.5%と4.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に5.2% 5.6%なると予測されています。主要情報4.5%収益成長率5.58%EPS成長率Chemicals 収益成長17.2%収益成長率4.2%将来の株主資本利益率5.24%アナリストカバレッジLow最終更新日13 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 14Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026.お知らせ • Mar 27+ 1 more updateNippon Shokubai Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Nippon Shokubai Co., Ltd. announced that they will report Q1, 2027 results at 1:00 PM, Tokyo Standard Time on Aug 07, 2026お知らせ • Feb 28Nippon Shokubai Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2026 results at 1:00 PM, Tokyo Standard Time on May 13, 2026お知らせ • Nov 18Nippon Shokubai Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Nippon Shokubai Co., Ltd. announced that they will report Q3, 2026 results at 1:00 PM, Tokyo Standard Time on Feb 05, 2026お知らせ • Aug 14Nippon Shokubai Co., Ltd. to Report Q2, 2026 Results on Nov 07, 2025Nippon Shokubai Co., Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025お知らせ • Jul 31Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 5,000,000 shares, representing 3.3% for ¥7,000 million.Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 3.3% of its issued share capital (excluding treasury stock), for a total purchase price of ¥7,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in response to change in the business environment. The program will be valid till February 27, 2026. As of June 30, 2025, the company has 151,691,868 issued shares (excluding treasury stock) and 4,308,132 treasury shares.お知らせ • Jun 26Nippon Shokubai's U.S. Group Company Acquires Iscc Plus Certification for Acrylic Acid and Superabsorbent PolymersNippon Shokubai Group companies in the United States have acquired ISCC PLUS certification for acrylic acid (hereinafter "AA") and superabsorbent polymers (hereinafter "SAP") produced locally. This enables Nippon Shokubai group to globally supply AA and SAP with a carbon footprint considered net zero. Through promoting the use of ISCC PLUS-certified AA and SAP, NipponShokubai Group aims to contribute to reducing environmental impact across the supply chain and to advancing a circular economy. Toward carbon neutrality by 2050, Nippon ShokubAI Group will continue to implement the "transformation" outlined in its long-term vision and mid-term management plan to enhance customer value. Nippon Shokubia Group commits and declares its compliance with the ISCC PLUS requirements in accordance with the latest ISCC regulations. ISCC (International Sustainability and Carbon Certification): It is a third-party certification program developed by International Sustainability and Carbon Certification (ISCC) system GmbH based in Germany to manage and guarantee sustainable raw materials and products such as biomass and recycled materials in the supply chain. Carbon footprint considered net zero: ISCC PLUS-certified products incorporate the biogenic CO2 removal associated with biomass growth into their carbon footprint calculations. The carbon footprints of these products are considered effectively net zero through the proportionally offset based on the share of biomass-derived feedstock allocated using the mass balance method. The mass balance method: When biomass-derived and petroleum-derived raw materials are used together in production, the proportion of biomass input can be allocated to specific end products. This method is officially recognized under the ISCC PLUS certification system.お知らせ • Jun 24Nippon Shokubai Plans to Expand Its Gmp-Compliant Nucleic Acid Drug API Manufacturing Capacity TenfoldNippon Shokubai CO., LTD. has announced a plan to expand its GMP (1)-compliant manufacturing capacity for nucleic acid drug "active pharmaceutical ingredients" (APIs) tenfold in response to rapidly growing global demand in the nucleic acid drug market. Nucleic acid drugs are generally defined as "chemically synthesized drugs with oligonucleotides as active ingredients that exert their effects without being translated into proteins." As a new modality following small molecule and antibody drugs, they are expected to be applied in areas such as rare diseases, neurological disorders, and cancers -- fields where conventional treatments have been limited. The capacity expansion will involve the installation of a large-scale production line with ten times the capacity (several kilograms per batch) of the company's existing line. The new facility is scheduled to begin operation in 2027, making it one of Japan's largest CDMOs, capable of manufacturing nucleic acid drug APIs for common diseases that require large-scale supply. The company will strengthen its manufacturing system to meet a wide range of needs, from non-clinical stages to large-scale commercial production. Leveraging Nippon Shokubai's long-standing expertise in organic synthesis and rigorous quality control systems, the company manufactures oligonucleotides and peptides, which are medium-sized molecule APIs. Its GMP-compliant facilities, among the most advanced in Japan, have been audited and visited by multiple pharmaceutical companies, all of which have given high evaluations, establishing Nippon ShokubAI's strong reputation in the industry. The company will continue to provide flexible contract manufacturing services that meet diverse needs and contribute to a sustainable society by ensuring a stable supply of medium-sized molecule APIs that support human health and life.お知らせ • May 31Nippon Shokubai Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Nippon Shokubai Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025お知らせ • May 13+ 3 more updatesNippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2025Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2025.お知らせ • Apr 02Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation.Nippon Shokubai Co., Ltd. (TSE:4114) agreed to acquire Emulsion Technology Co.,Ltd. from JSR Corporation for ¥7.2 billion on November 12, 2024. As part of consideration, ¥7.2 billion is paid towards common equity of Emulsion Technology Co.,Ltd. For the period ending March 31, 2024, Emulsion Technology Co.,Ltd. reported total revenue of ¥13.3 billion, EBIT of ¥918 million and net income of ¥647 million. The expected completion of the transaction is April 1, 2025. Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation on April 1, 2025.お知らせ • Feb 06Nippon Shokubai Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2025 results at 3:00 PM, Tokyo Standard Time on May 13, 2025お知らせ • Dec 12Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd.Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd. on December 9, 2024. Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Lilac Pharma Co., Ltd. on December 9, 2024.お知らせ • Nov 11Nippon Shokubai Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Nippon Shokubai Co., Ltd. announced that they will report Q3, 2025 results at 3:00 PM, Tokyo Standard Time on Feb 06, 2025お知らせ • Aug 15Nippon Shokubai Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Nippon Shokubai Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024お知らせ • May 15Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024.お知らせ • May 14Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 4,000,000 shares, representing 2.59% for ¥5,000 million.Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 4,000,000 shares, representing 2.59% of its issued share capital (excluding treasury stock), for a total purchase price of ¥5,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in response to change in the business environment. The program will be valid till February 28, 2025. As of March 31, 2024, the company has 154,642,750 issued shares (excluding treasury stock) and 1,357,240 treasury shares.お知らせ • Mar 02Nippon Shokubai Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2024 results on May 13, 2024お知らせ • Feb 09+ 1 more updateNippon Shokubai Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2023Nippon Shokubai Co., Ltd. announced that For the fiscal year ending March 31, 2023, the company to forecasts to pay a dividend of JPY 90.00 per share as compared to JPY 90.00 per share paid a year ago.業績と収益の成長予測OTCPK:NSHK.F - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2029465,35019,70020,35056,60023/31/2028449,50018,65011,80053,20023/31/2027435,10017,4002,92049,43523/31/2026399,89816,7643,80953,544N/A12/31/2025400,05817,7407,02447,858N/A9/30/2025402,66716,0815,66849,535N/A6/30/2025405,49817,1973,06545,287N/A3/31/2025409,34617,39411,97046,974N/A12/31/2024408,26715,22819,28551,415N/A9/30/2024404,58413,07224,25447,508N/A6/30/2024399,74211,06439,47660,233N/A3/31/2024392,00911,00837,31357,880N/A12/31/2023386,3938,75933,85954,294N/A9/30/2023394,20112,18439,62060,584N/A6/30/2023405,42516,37620,07843,177N/A3/31/2023419,56819,39218,36241,447N/A12/31/2022425,01724,82316,62039,738N/A9/30/2022415,97325,43911,68733,270N/A6/30/2022394,74125,66816,66938,103N/A3/31/2022369,29323,72012,80235,058N/A12/31/2021347,5156,8977,46233,229N/A9/30/2021321,4832,63478928,640N/A6/30/2021296,284-6,8202,83232,011N/A3/31/2021273,163-10,8993,89135,277N/A12/31/2020270,5063,284-93234,167N/A9/30/2020273,5264,1804,14537,935N/A6/30/2020288,0969,393-1,49333,858N/A3/31/2020302,15011,0943,47037,499N/A12/31/2019298,16313,147N/A49,367N/A9/30/2019314,76616,652N/A48,327N/A6/30/2019326,68119,538N/A43,580N/A3/31/2019338,86923,849N/A35,918N/A12/31/2018347,43525,698N/A30,862N/A9/30/2018341,15925,195N/A29,595N/A6/30/2018331,68525,465N/A38,398N/A3/31/2018322,80124,280N/A38,823N/A12/31/2017327,82522,947N/A39,470N/A9/30/2017314,70622,870N/A38,590N/A6/30/2017302,27021,004N/A36,968N/A3/31/2017293,97019,361N/A37,474N/A12/31/2016284,71520,166N/A40,626N/A9/30/2016294,37320,028N/A44,579N/A6/30/2016310,20122,421N/A42,987N/A3/31/2016323,12426,003N/A53,264N/A12/31/2015347,36626,142N/A48,344N/A9/30/2015362,63526,089N/A45,438N/A6/30/2015368,54422,979N/A45,170N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: NSHK.Fの予測収益成長率 (年間4.5% ) は 貯蓄率 ( 3.5% ) を上回っています。収益対市場: NSHK.Fの収益 ( 4.5% ) US市場 ( 16.8% ) よりも低い成長が予測されています。高成長収益: NSHK.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: NSHK.Fの収益 ( 4.2% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: NSHK.Fの収益 ( 4.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: NSHK.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 5.2 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 07:12終値2026/03/02 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nippon Shokubai Co., Ltd. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12 アナリスト機関null nullAstris Advisory Japan, K.K.Mikiya YamadaBarclaysTakashi EnomotoBofA Global Research9 その他のアナリストを表示
お知らせ • May 14Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2026.
お知らせ • Mar 27+ 1 more updateNippon Shokubai Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026Nippon Shokubai Co., Ltd. announced that they will report Q1, 2027 results at 1:00 PM, Tokyo Standard Time on Aug 07, 2026
お知らせ • Feb 28Nippon Shokubai Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2026 results at 1:00 PM, Tokyo Standard Time on May 13, 2026
お知らせ • Nov 18Nippon Shokubai Co., Ltd. to Report Q3, 2026 Results on Feb 05, 2026Nippon Shokubai Co., Ltd. announced that they will report Q3, 2026 results at 1:00 PM, Tokyo Standard Time on Feb 05, 2026
お知らせ • Aug 14Nippon Shokubai Co., Ltd. to Report Q2, 2026 Results on Nov 07, 2025Nippon Shokubai Co., Ltd. announced that they will report Q2, 2026 results on Nov 07, 2025
お知らせ • Jul 31Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 5,000,000 shares, representing 3.3% for ¥7,000 million.Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 shares, representing 3.3% of its issued share capital (excluding treasury stock), for a total purchase price of ¥7,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in response to change in the business environment. The program will be valid till February 27, 2026. As of June 30, 2025, the company has 151,691,868 issued shares (excluding treasury stock) and 4,308,132 treasury shares.
お知らせ • Jun 26Nippon Shokubai's U.S. Group Company Acquires Iscc Plus Certification for Acrylic Acid and Superabsorbent PolymersNippon Shokubai Group companies in the United States have acquired ISCC PLUS certification for acrylic acid (hereinafter "AA") and superabsorbent polymers (hereinafter "SAP") produced locally. This enables Nippon Shokubai group to globally supply AA and SAP with a carbon footprint considered net zero. Through promoting the use of ISCC PLUS-certified AA and SAP, NipponShokubai Group aims to contribute to reducing environmental impact across the supply chain and to advancing a circular economy. Toward carbon neutrality by 2050, Nippon ShokubAI Group will continue to implement the "transformation" outlined in its long-term vision and mid-term management plan to enhance customer value. Nippon Shokubia Group commits and declares its compliance with the ISCC PLUS requirements in accordance with the latest ISCC regulations. ISCC (International Sustainability and Carbon Certification): It is a third-party certification program developed by International Sustainability and Carbon Certification (ISCC) system GmbH based in Germany to manage and guarantee sustainable raw materials and products such as biomass and recycled materials in the supply chain. Carbon footprint considered net zero: ISCC PLUS-certified products incorporate the biogenic CO2 removal associated with biomass growth into their carbon footprint calculations. The carbon footprints of these products are considered effectively net zero through the proportionally offset based on the share of biomass-derived feedstock allocated using the mass balance method. The mass balance method: When biomass-derived and petroleum-derived raw materials are used together in production, the proportion of biomass input can be allocated to specific end products. This method is officially recognized under the ISCC PLUS certification system.
お知らせ • Jun 24Nippon Shokubai Plans to Expand Its Gmp-Compliant Nucleic Acid Drug API Manufacturing Capacity TenfoldNippon Shokubai CO., LTD. has announced a plan to expand its GMP (1)-compliant manufacturing capacity for nucleic acid drug "active pharmaceutical ingredients" (APIs) tenfold in response to rapidly growing global demand in the nucleic acid drug market. Nucleic acid drugs are generally defined as "chemically synthesized drugs with oligonucleotides as active ingredients that exert their effects without being translated into proteins." As a new modality following small molecule and antibody drugs, they are expected to be applied in areas such as rare diseases, neurological disorders, and cancers -- fields where conventional treatments have been limited. The capacity expansion will involve the installation of a large-scale production line with ten times the capacity (several kilograms per batch) of the company's existing line. The new facility is scheduled to begin operation in 2027, making it one of Japan's largest CDMOs, capable of manufacturing nucleic acid drug APIs for common diseases that require large-scale supply. The company will strengthen its manufacturing system to meet a wide range of needs, from non-clinical stages to large-scale commercial production. Leveraging Nippon Shokubai's long-standing expertise in organic synthesis and rigorous quality control systems, the company manufactures oligonucleotides and peptides, which are medium-sized molecule APIs. Its GMP-compliant facilities, among the most advanced in Japan, have been audited and visited by multiple pharmaceutical companies, all of which have given high evaluations, establishing Nippon ShokubAI's strong reputation in the industry. The company will continue to provide flexible contract manufacturing services that meet diverse needs and contribute to a sustainable society by ensuring a stable supply of medium-sized molecule APIs that support human health and life.
お知らせ • May 31Nippon Shokubai Co., Ltd. to Report Q1, 2026 Results on Aug 07, 2025Nippon Shokubai Co., Ltd. announced that they will report Q1, 2026 results on Aug 07, 2025
お知らせ • May 13+ 3 more updatesNippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2025Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 19, 2025.
お知らせ • Apr 02Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation.Nippon Shokubai Co., Ltd. (TSE:4114) agreed to acquire Emulsion Technology Co.,Ltd. from JSR Corporation for ¥7.2 billion on November 12, 2024. As part of consideration, ¥7.2 billion is paid towards common equity of Emulsion Technology Co.,Ltd. For the period ending March 31, 2024, Emulsion Technology Co.,Ltd. reported total revenue of ¥13.3 billion, EBIT of ¥918 million and net income of ¥647 million. The expected completion of the transaction is April 1, 2025. Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Emulsion Technology Co.,Ltd. from JSR Corporation on April 1, 2025.
お知らせ • Feb 06Nippon Shokubai Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2025 results at 3:00 PM, Tokyo Standard Time on May 13, 2025
お知らせ • Dec 12Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd.Nippon Shokubai Co., Ltd. (TSE:4114) acquired Lilac Pharma Co., Ltd. on December 9, 2024. Nippon Shokubai Co., Ltd. (TSE:4114) completed the acquisition of Lilac Pharma Co., Ltd. on December 9, 2024.
お知らせ • Nov 11Nippon Shokubai Co., Ltd. to Report Q3, 2025 Results on Feb 06, 2025Nippon Shokubai Co., Ltd. announced that they will report Q3, 2025 results at 3:00 PM, Tokyo Standard Time on Feb 06, 2025
お知らせ • Aug 15Nippon Shokubai Co., Ltd. to Report Q2, 2025 Results on Nov 07, 2024Nippon Shokubai Co., Ltd. announced that they will report Q2, 2025 results on Nov 07, 2024
お知らせ • May 15Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024Nippon Shokubai Co., Ltd., Annual General Meeting, Jun 20, 2024.
お知らせ • May 14Nippon Shokubai Co., Ltd. (TSE:4114) announces an Equity Buyback for 4,000,000 shares, representing 2.59% for ¥5,000 million.Nippon Shokubai Co., Ltd. (TSE:4114) announces a share repurchase program. Under the program, the company will repurchase up to 4,000,000 shares, representing 2.59% of its issued share capital (excluding treasury stock), for a total purchase price of ¥5,000 million. The purpose of the program is to improve the shareholder return as well as capital efficiency and to implement flexible capital policy in response to change in the business environment. The program will be valid till February 28, 2025. As of March 31, 2024, the company has 154,642,750 issued shares (excluding treasury stock) and 1,357,240 treasury shares.
お知らせ • Mar 02Nippon Shokubai Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024Nippon Shokubai Co., Ltd. announced that they will report fiscal year 2024 results on May 13, 2024
お知らせ • Feb 09+ 1 more updateNippon Shokubai Co., Ltd. Provides Dividend Forecast for the Fiscal Year Ending March 31, 2023Nippon Shokubai Co., Ltd. announced that For the fiscal year ending March 31, 2023, the company to forecasts to pay a dividend of JPY 90.00 per share as compared to JPY 90.00 per share paid a year ago.